The global epigenetics market size is expected to reach USD 39.15 billion by 2030, registering a CAGR of 15.10% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is being driven by factors, such as the rise in funding, investment & regulatory approvals for epigenetics research & development, the expansion of the use of epigenetic enzymes in drug discovery & development, and the decreasing cost of genome sequencing. Since epigenetics has demonstrated beneficial applications outside of cancer, commercial expansion is envisaged.The rising demand for understanding epigenetic alterations at the molecular level, as well as the advancement of medicinal treatments, would likely push these organizations to support research and development programs.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/epigenetics-market

Furthermore, initiatives, such as the Epidemiology and Genomics Research Program (EGRP), provide incentives for research efforts aimed at better-comprehending cancer genesis and consequences.A few organizations that help fuel the market's rise are the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institutes of Health (NIH). These organizations support funding and help for initiatives involving product development and R&D in the field of epigenetics. For instance, the National Institutes of Health aggressively promotes cutting-edge epigenetic research worldwide through its common fund epigenomics program.

Epigenetics Market Report Scope

Epigenetics Market Report Highlights

• By product, the reagents segment accounted for the largest revenue share of 31.50% in 2022 owing to the existence of a number of technology platforms that facilitate analysis at gene, protein, or cellular levels, which encourages innovation in the global marketplace
• By application, the oncology segment accounted for the largest revenue share of 69.23% in 2022. The segment is expanding as a result of the increased incidence of cancer and the number of cancer-related fatalities globally
• By technology, the histone acetylation segment is anticipated to register the fastest CAGR of 15.8% from 2023 to 2030 due to its improved efficacy as a result of the development of innovative methods
• North America dominated the market with the highest revenue share of 38.18% in 2022 owing to government support and increasing R&D funding by government and private organizations

Epigenetics Market Segmentation

Grand View Research has segmented the global epigenetics market report on the basis of product, application, technology, and region:

Epigenetics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagents
• Kits
  • Chip sequencing kit
  • Whole Genomic Amplification Kit
  • Bisulfite Conversion kit
  • RNA sequencing kit
  • Others
• Instruments
• Enzymes
• Services

Epigenetics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large noncoding RNA
• MicroRNA Modification
• Chromatin structures

Epigenetics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology
  • Solid Tumors
  • Liquid Tumors
• Non-Oncology
  • Inflammatory Diseases
  • Metabolic Diseases
  • Infectious Diseases
  • Cardiovascular Diseases

Regional Insights

North America dominated the market with a revenue share of 38.18% in 2022. The large share is mainly attributed to government support and the presence of major companies. High awareness among people, advanced medical infrastructure, and high R&D expenditure are some of the other factors that support the market growth in the region. Moreover, the high prevalence of chronic diseases and increasing investment by market participants for the development of epigenetics will boost regional growth further. For instance, Chroma Medicine, Inc. (Chroma), a brand-new genomic medicine business that pioneered epigenetic editing, started with USD 125 million in investment in November 2021 to treat a variety of disorders and become the most commonly used technology for gene regulation.

The market in the Asia Pacific region is projected to grow at the fastest CAGR of 17.2% from 2023 to 2030. The Asia Pacific market is expected to rise owing to increasing investment in research & development activities by the government and growing incidences of cancer. For instance, in 2022, the WHO South-East Asia Region recorded 1.4 million cancer-related fatalities and approximately 2.2 million new cases, accounting for over one out of every ten deaths in the region. Lung cancer caused 10.6% of cancer-related fatalities, followed by breast cancer (9.4%), cervical cancer (8%), liver cancer (6.6%), and oral cavity cancer at 6.4%. The growing adoption of epigenetics in developing economies will boost regional market growth during the forecast period.

List of Key Players of Epigenetics Market

• Roche Diagnostics
• Thermo Fisher Scientific, Inc.
• Eisai Co. Ltd.
• Novartis AG
• Element Biosciences, Inc.
• Dovetail Genomics LLC.
• Illumina, Inc.
• ValiRx Plc.
• Abcam plc.

 Authoritative Research: https://www.grandviewresearch.com/industry-analysis/epigenetics-market